Our Pipeline

Novel & Improved NMDAR PAMs

The NMDA receptor is a key receptor for glutamate, the brain's primary excitatory neurotransmitter, and it plays a central role in regulating synaptic plasticity, learning/memory, cognition and mood.

Gate's lead programs are NMDAR positive allosteric modulators (PAMs) that bind to a unique site on the receptor to directly enhance glutamate signaling and improve synaptic function. Our mechanism is highly differentiated from other NMDAR-targeted therapies by avoiding the severe side effects of antagonists (i.e. ketamine) and overstimulation by other PAMs.

Directly enhancing synaptic function with our novel NMDAR PAMs represents a safer approach to achieve rapid and long-lasting treatment outcomes.

services image

Clinical Studies

Phase 2 Clinical Study

Zelquistinel (GATE-251)

Phase 2 Study of Once-Weekly Oral Zelquistinel In Adults with Major Depressive Disorder

Phase 2 Clinical Study

Apimostinel (GATE-202)

Phase 2 study of single-dose apimostinel in combination with ASAT digital training in adults with depression